Introduction {#Sec1}
============

Herpes zoster (HZ), also known as shingles, is a painful rash mainly affecting people with a weakened immune system due to ageing, malignant disease or immunosuppressive medication \[[@CR1]\]. After primary infection with varicella zoster virus (VZV), which leads to varicella, also known as chickenpox, the virus remains dormant in the cranial nerve, dorsal root and autonomic ganglia. As cell-mediated immunity against VZV wanes because of advanced age or an immunocompromised state, the virus may replicate again leading to HZ \[[@CR2]\]. As a result, a unilateral, vesicular rash develops in the affected dermatomes, which usually resolves after 4 weeks from symptom onset. However, several complications may arise, with the most common being postherpetic neuralgia (PHN), i.e., pain that persists long after the initial rash has resolved \[[@CR3], [@CR4]\]. The reported risk of developing PHN varies greatly because of differences in definition and study design \[[@CR5]\]. Most commonly, PHN is defined as pain that persists for ≥ 90 days after initial rash development; using this definition, between 5 and 30% of patients with HZ experience PHN \[[@CR5]\].

The majority of adults will have been infected with VZV during childhood or early adulthood as a result of varicella infection. In Japan, \> 90% of people aged ≥ 20 years test positive for anti-VZV antibodies and are at risk of developing HZ \[[@CR6]\]. The lifetime risk is estimated at 30% and HZ incidence rises steeply after the age of 50 years \[[@CR5]\]. In Japan, the reported HZ incidence was 10.9 per 1000 person-years in people aged ≥ 50 years, and approximately 20% of patients proceeded to develop PHN \[[@CR7]\].

In addition, epidemiological studies indicate an increase in the number of HZ cases, which exceeds that solely predicted by an ageing population \[[@CR5], [@CR8], [@CR9]\]. In Japan, which has purportedly the highest proportion of elderly citizens worldwide, HZ and PHN pose a substantial disease burden in terms of loss of quality of life \[[@CR10]\] and health care costs \[[@CR11]\]. The economic burden is driven by medical costs relating to medications, outpatient visits and hospitalizations and was 2.7 times higher for HZ with PHN compared with HZ without any complications \[[@CR11]\]. Current treatment options, including antivirals, analgesics and tricyclic antidepressants in case of PHN, provide only symptomatic relief and score low in terms of patient satisfaction with treatment efficacy \[[@CR12]\]. Furthermore, based on a systematic review of randomized controlled trials, antivirals administered immediately at rash onset were no better than placebo in preventing PHN \[[@CR13]\]. Thus, boosting cell-mediated immunity through vaccination is an attractive strategy to lower the incidence of HZ and PHN. To date, two vaccines have been developed for HZ prevention and have received approval in several countries. The first is zoster vaccine live (ZVL, Zostavax), a one-dose vaccine using the same Oka strain as in the varicella vaccine. ZVL is however not available in Japan. Recently, another HZ-specific vaccine has been developed: the adjuvant recombinant zoster vaccine (RZV, Shingrix), a two-dose subunit vaccine that combines VZV glycoprotein E, an important and highly abundant protein found on the VZV, with the proprietary adjuvant system AS01~B~ \[[@CR14]\]. In Japan, RZV gained approval in March 2018 for HZ prevention in individuals aged ≥ 50 years. In 2017, the Advisory Committee on Immunization Practices (ACIP) in the USA issued a preferential recommendation for the use of RZV for preventing shingles and related complications in people aged ≥ 50 years \[[@CR15]\]. Similar recommendations have been made by the National Advisory Committee on Immunization (NACI) in Canada \[[@CR16]\]. In Germany, the Standing Committee on Vaccination (STIKO) has recently issued its recommendation for RZV vaccination in people with underlying diseases aged between 50 and 60 as well as a general recommendation for RZV vaccination in people aged ≥ 60 years \[[@CR17]\]. In Japan, the already existing varicella vaccine live (VVL) was approved by the Ministry of Health, Labour and Welfare (MHLW) in March 2016 for extended use in adults aged ≥ 50 years for HZ prevention on the basis that its titre is comparable to ZVL \[[@CR18]\].

The public health impact of introducing routine HZ vaccination with either VVL or RZV in Japan has recently been investigated \[[@CR19]\]. Both vaccines significantly reduced the disease burden and resource utilization associated with HZ and PHN. RZV had a larger impact compared with VVL, avoiding approximately three to four times as many HZ and PHN cases and leading to a four- to five-fold higher reduction in the number of hospitalizations and outpatient visits \[[@CR19]\]. The current vaccination schedule in Japan recommends several vaccines in adults aged ≥ 65 years, including influenza and pneumococcal vaccine. Therefore, the objective of this study was to evaluate the cost-effectiveness of RZV in preventing HZ and its complications compared with no vaccination in Japanese adults aged 65 years and older to provide supportive evidence for policy making. In scenario analyses, the impact of age at vaccination on the incremental cost-effectiveness ratio (ICER) was evaluated by simulating cohorts aged 50, 60 and ≥ 70 years.

Methods {#Sec2}
=======

Model Overview {#Sec3}
--------------

The ZOster ecoNomic Analysis (ZONA) model, a static multi-cohort Markov model, was developed to assess the cost-effectiveness of RZV in different cohorts \[[@CR20], [@CR21]\] and adapted for the Japanese context.

The model considers individuals aged ≥ 50 years partitioned into five age groups (50--59, 60--64, 65--59, 70--79 and ≥ 80 years) and follows all individuals within a cohort for their remaining lifetime from the year of vaccination. Individuals remain in their initial cohort and events are summed up in that cohort only. For the population of individuals aged ≥ 65 years, the results for age groups of 65--69, 70--79 and ≥ 80 years are combined. During each annual cycle, people may transition between different health states (no HZ, HZ, PHN, HZ-related complications other than PHN, recurrent HZ, HZ-related death and death due to natural cause) according to age-specific probabilities.

Vaccination with RZV is compared with no vaccination. Where possible, Japanese-specific data were selected for relevant input parameters.

Methodological Assumptions {#Sec4}
--------------------------

The base case analysis for the ICER included a cohort of 1 million individuals aged ≥ 65 years mimicking the Japanese age-distribution. Simulating a 1 million cohort allowed for comparison with other cost-effectiveness analyses carried out for different countries but using the same cohort size \[[@CR20], [@CR21]\]. A payer's perspective including only direct medical costs was used for the base-case scenario based on the analysis of economic evaluation of vaccines and the guideline for economic evaluation of drugs/medical devices in Japan \[[@CR22], [@CR23]\]. Costs and outcomes were evaluated over the remaining lifetime and discounted at 2% annually \[[@CR22], [@CR23]\]. Results from a societal perspective were presented as part of scenario analyses.

Model Inputs and Outputs {#Sec5}
------------------------

### Demographic and Epidemiological Data {#Sec6}

Age-stratified population figures and all-cause mortality rates in 5-year age groups starting at age 50 years were retrieved from the Japanese Government Statistics provided by e-Stat, including estimates of the population and abridged life tables as of 2017 \[[@CR24]\].

Epidemiological input variables used in the base case analysis were sourced from published literature, using Japanese literature where possible (Table [1](#Tab1){ref-type="table"}). HZ incidence rates and the proportion of patients with HZ developing PHN were derived from a prospective cohort study in Japanese people aged ≥ 50 years who were followed over a 3-year period \[[@CR7]\]. This study was considered to provide the most reliable epidemiological information regarding HZ incidence because of its community-based approach (rather than institution-based) and prospective enrolment including adults aged ≥ 50 years without applying additional selection criteria, thereby closely mimicking the real-world population. Data from other studies were used to inform upper and lower bounds used in sensitivity and scenario analyses \[[@CR25]--[@CR28]\]. HZ complication rates other than PHN were derived from a study by Nakamura et al. \[[@CR11]\]. The incidences of recurrent HZ and PHN were assumed to be the same as those for the first occurrence based on several long-term studies showing that incidence of first-time and recurrent HZ was comparable \[[@CR5], [@CR29]\]. HZ-related mortality rates were retrieved from "Vital Statistics (2017)" provided by e-Stat \[[@CR24]\].Table 1Epidemiological input values and sources applied in base case, sensitivity and scenario analysesYears of ageBase valueLower bound for DSAUpper bound for DSASE for PSAPopulation size used to determine the proportions in the 1 million cohort 50--5915,749,000------ 60--647,805,000------ 65--699,921,000------ 70--7914,486,000------ ≥ 8010,744,000------ *Source*(*24*)*NANA*--Annual incidence of initial and recurrent HZ 50--590.00920------ 60--690.009600.007680.011520.000980 70--790.012900.010320.015480.001320 ≥ 800.012600.010080.015120.001290 *Source*(*7*)^a^− *20%:* (*26, 27*)^a^+ *20*%: *assumption*^a^Initial and recurrent HZ cases with PHN (%) 50--5914.60------ 60--6914.607.3017.520.0261 70--7920.2010.1024.240.0361 ≥ 8032.9016.4539.480.0588 *Source*(*7*)^b^− *50%:* (*25*)^b^+ *20*%*: assumption*^b^HZ-related complications other than PHN (%) 50--695.11.98.30.0165 ≥ 7010.66.714.50.0201 *Source*(*11*)^c^(*11*)^c^(*11*)^c^HZ mortality rate (%) 50--690.0000------ 70--740.0020------ 75--790.0092------ 80--840.0210------ 85--890.0467------ 90--940.1204------ 95--990.1960------ ≥ 1000.9476------ *Source*(*7, 24*)*NANA*--*DSA* deterministic sensitivity analysis, *HZ* herpes zoster, *PHN* postherpetic neuralgia, *PSA* probabilistic sensitivity analysis, *RZV* recombinant zoster vaccine, *SE* standard error^a^Takao et al. reported an incidence rate of HZ in a community-based prospective cohort study \[[@CR7]\]. The lower bound estimates were obtained from Toyama et al. \[[@CR26], [@CR27]\], and − 20% was set based on the adjusted values by the updated HZ incidence (4.15 in 1997--2006 vs. 6.07 in 2017); assumed + 20% of base case for the upper bound. The recurrent HZ incidence was assumed to be the same as the initial HZ incidence^b^The percentage of HZ with PHN was obtained from the same data source as the HZ incidence. The lower bound estimates were obtained from Sato et al. \[[@CR25]\]; − 50% was set based on the ratio of total PHN proportion in the two studies (9.2%/19.7%); assumed + 20% of the base case for the upper bound. The PHN proportion among HZ was assumed to be the same for both initial and recurrent cases^c^Nakamura et al. reported overall incidence of non-pain complications including ocular, neurological and cutaneous ones in a prospective, observational cohort study of Japanese adults aged ≥ 60 \[[@CR11]\]. The incidence at ages 50--59 was assumed to be the same as that at ages 60--69. Ranges were set as 95% confidence intervals calculated from the published data in Nakamura et al. \[[@CR11]\]

### Vaccine Efficacy and Waning {#Sec7}

Recombinant zoster vaccine efficacy (VE) and decrease of VE over time (waning) were derived from data collected in two phase III clinical trials \[[@CR30], [@CR31]\] as described in detail elsewhere \[[@CR21], [@CR32]\] (Supplementary Material \[S\]; Table S1). The vaccination coverage was assumed to be the same as that for a pneumococcal polysaccharide vaccine for older adults in Japan \[[@CR33]\], i.e., 40%. In the base case analysis, second dose compliance was set to 95%, in line with clinical trial data and in the absence of data regarding real-life second dose compliance in Japanese older adults \[[@CR19], [@CR30], [@CR31]\]. It should be noted that compliance rates \> 95% for the second or third dose of paediatric vaccines have been reported in Japan \[[@CR33]\]. Compliance rates may however be different in the adult population; therefore, sensitivity analyses were carried out where second dose compliance was varied from 70 to 100%.

### Utilities {#Sec8}

Utilities for the base case, sensitivity and scenario analyses were obtained from the same prospective cohort study from which cost data were derived \[[@CR10]\] (Table [2](#Tab2){ref-type="table"}). Quality-adjusted life year (QALY) loss due to HZ (with and without PHN) was calculated using the reported utility values and the PHN duration \[[@CR28]\] (Table S2).Table 2Utility input values and sources applied in base case, sensitivity and scenario analysesBase valueLower bound for DSAUpper bound for DSAStandard error for PSABaseline utility 50--59 YOA0.962------ 60--69 YOA0.975------ 70--79 YOA0.942------ ≥ 80 YOA0.883------ *Source*(*10*)^a^*NANA*QALY loss per HZ Without PHN  50--59 YOA0.014------  60--69 YOA0.0150.01200.01800.0015  70--79 YOA0.0200.01600.02400.0020  ≥ 80 YOA0.0170.01360.02040.0017 With PHN  50--59 YOA0.118------  60--69 YOA0.1350.10800.16200.0138  70--79 YOA0.1540.12320.18480.0157  ≥ 80 YOA0.1790.14320.21480.0183 *Source*(*10*); *Table S2*^b^− *20%: Assumption*^b^+ *20%: Assumption*^b^QALY loss from adverse event Local/general0.0001------ Hospitalization0.0082------ *Source*(*43*)^c^*NANADSA* deterministic sensitivity analysis, *HZ* herpes zoster, *NA* not applicable, *PHN* postherpetic neuralgia, *PSA* probabilistic sensitivity analysis, *QALY* quality-adjusted life year, *YOA* years of age^a^Assumed to be the same as the utility at day 90 after HZ onset for HZ patients without PHN obtained from a prospective cohort study reported by Mizukami et al. \[[@CR10]\]^b^QALY loss was estimated by the same data source for baseline utility. QALY loss per HZ without PHN was calculated using the utilities between day 0 and day 90 for HZ patients without PHN; QALY loss per HZ with PHN was calculated using the utilities between day 0 and day 90 for HZ patients with PHN and PHN duration reported by Imafuku et al. \[[@CR28]\], as illustrated in Table S2. Age 50--59 was assumed to be the same as age 60--64, assumed to be a range of ± 20% in the sensitivity analysis^c^Applied QALY losses for local/general and hospitalization adverse events (AEs) to be consistent with Le and Rothberg \[[@CR43]\]; it is implicitly assumed that persons requiring an outpatient or ER visit from AEs experienced the QALY loss related to a local/general reaction. The model calculates a weighted AE QALY loss per dose based on the incidence of the four AEs and the QALY losses per event. The weighted QALY loss per dose is varied by + 100% and − 50% in sensitivity analysis, so no ranges are used for the individual costs per AE

### Costs {#Sec9}

The cost inputs applied in the base case, sensitivity and scenario analyses are summarized in Table [3](#Tab3){ref-type="table"}. Direct medical costs per HZ case were based on the data from a prospective cohort study \[[@CR11]\] and retrospective database study \[[@CR34]\]. The costs reported by Nakamura et al. were adjusted by the hospitalization rate reported by Sato et al., resulting from the same prospective cohort study \[[@CR25]\]. In addition, the cost for patients with PHN was converted into the annual cost by adding the treatment cost of PHN reported by Honda et al. \[[@CR34]\]. An official price for RZV in Japan has not been disclosed or listed yet. Therefore, for the base case analysis and excluding consumption tax, an RZV hypothetical price of ¥12,000 per dose was assumed with a range of ¥10,000--¥15,000 used in sensitivity analyses, which is broadly similar to the price assumed in the US and German cost-effectiveness publications \[[@CR20], [@CR21]\]. The administration cost per dose was set to ¥3170 based on a medical fee point scheme \[[@CR35]\]. A consumption tax of 8% was added to all costs. Indirect costs due to HZ included the productivity loss for patients and their caregivers \[[@CR11]\]. The productivity loss for patients was calculated based on the number of visits and admission days in HZ with and without PHN (Table S3) and standardized by an hourly wage and an employment rate obtained from "Basic survey of wage structure (2017)" and "Survey of labour force (2017)", respectively, by age groups \> 50 in Japan \[[@CR24]\]. As there is no information on adverse event costs by vaccination, the costs by categories were assumed based on an expert opinion.Table 3Cost input values and sources applied in base case, sensitivity and scenario analysesBase valueLower bound for DSAUpper bound for DSAStandard error for PSADirect medical costs Costs per HZ case  Without any complications38,47135,57541,3671478  With PHN127,07990,164163,99418,834  With non PHN-related complications72,78937,482108,09618,014 *Source*(*11, 25, 34*)^a^(*11*)^a^(*11*)^a^Vaccination costs RZV vaccine price per dose12,96010,800^b^16,200^b^--  *SourceAssumption* ^c^*AssumptionAssumption*-- Administration cost per dose34242568^b^4280^b^--  *SourceAssumption* ^d^− *25%: Assumption*+ *25%: Assumption*--Adverse event costs Local/general0------ Outpatient3957.5------ ER8757.5------ Hospitalization225,750------ *SourceAssumption* ^e^*NANA*--Indirect costs Costs per HZ case  Without PHN   50--59 YOA17,747------   60--69 YOA15,12811,34618,9101929   70--79 YOA11,892891914,8651517   ≥ 80 YOA15,11511,33618,8941928  With PHN   50--59 YOA57,662------   60--69 YOA32,73324,55040,9164175   70--79 YOA20,29715,22325,3712589   ≥ 80 YOA19,04614,28523,8082429  *SourceDerived from* (*11*)^f^− *25%: Assumption*+ *25%: AssumptionDSA* deterministic sensitivity analysis, *ER* emergency room, *HZ* herpes zoster, *PHN* postherpetic neuralgia, *PSA* probabilistic sensitivity analysis, *RZV* recombinant zoster vaccine, *YOA* years of age^a^Nakamura et al. reported HZ-related costs for patients with HZ without any complications, with PHN, and with non-pain complications in a prospective cohort study \[[@CR11]\]. The costs were adjusted by hospitalization rate reported by Sato et al. \[[@CR25]\]. In addition, the cost for patients with PHN was converted into the annual cost by adding the PHN treatment cost for 3 months (= 95,809/6 months × 3/6 months × 50%) reported by Honda et al. \[[@CR34]\]. Calculated a range from the standard error of the data reported by Nakamura et al. \[[@CR11]\]^b^This input was varied in one-way sensitivity analysis but was held at its base value(s) in probabilistic sensitivity analysis^c^Assumed the price from the vaccination cost comparable to that used in the cost-effectiveness analysis in the US \[[@CR21]\] and Germany \[[@CR20]\]. Cost input was the price including 8% consumption tax^d^Calculated based on medical fee point scheme in 2016; (2820 for initial visit + 200 for biologics + 150 for injection) × 1.08 = ¥3424^e^Assumed based on medical fee point scheme in 2016 according to expert opinion; no healthcare resource utilization for local/general; 2820 for initial visit + 680 for prescription + (15.9 (Sodium Loxoprofen) + 14.6 (Rebamipide)) × 15T = ¥3957.5 for Outpatient; 4800 for visit between 22:00 and 6:00 + AE cost for outpatient = ¥8757.5 for ER. Assumed based on diagnosis procedure combination (DPC) point scheme in 2016; DPC code of 080100 (drug eruption) with admission for median duration, 25,940 × 5 + 19,210 × 5 = ¥225,750 for Hospitalization. The model calculated a weighted adverse event (AE) cost per dose based on the incidence of the four AEs and the costs per event. The weighted cost per dose was varied by + 100% and − 50% in sensitivity analysis, so no ranges were used for the individual costs per AE^f^Indirect costs include productivity loss of patients and their caregivers. The productivity loss of patients was calculated based on the number of visits and admission days (Table S3). Assumed to be a range of ± 25% in sensitivity analysis

Health outcomes included the numbers of HZ, PHN cases and HZ complications other than PHN avoided and number of deaths avoided from HZ over the entire time horizon. Costs included vaccinations costs, direct costs and indirect costs (for the societal perspective only). All costs were expressed in Japanese yen (¥) as of 2017.

The resulting ICERs were compared with a willingness-to-pay (WTP) threshold of ¥5,000,000 per QALY gained, commonly used in Japan \[[@CR36]\].

Sensitivity and Scenario Analyses {#Sec10}
---------------------------------

Deterministic one-way sensitivity analyses (DSAs) were performed by varying each of the model's input variables one at a time over the ranges presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} and in Table S1. Ranges were chosen based on alternative values reported in the literature. Probabilistic sensitivity analyses (PSAs) were conducted to observe the variation in cost-effectiveness. In PSA, 5000 Monte Carlo simulations were carried out where input values were simultaneously sampled from probability distributions. Cost parameters were sampled across gamma or uniform distributions. A uniform distribution was used for second dose compliance, while a beta distribution was applied to all other parameters.

Threshold analyses were conducted on different parameters, i.e., initial efficacy of RZV (two doses), HZ incidence (initial and recurrent), vaccine price, waning of efficacy and QALY loss associated with HZ (with/without PHN). These parameters were varied by steps of 10% from − 100 to + 100% to assess the impact on the ICER and the potential to reach the WTP threshold.

Scenario analyses were performed to explore the impact of age at vaccination on the ICER, including cohorts of adults aged 50, 60 and ≥ 70.

Compliance with Ethics Guidelines {#Sec11}
---------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec12}
=======

Base-Case Analysis {#Sec13}
------------------

Results for the base case analysis for a cohort of 1 million Japanese adults aged ≥ 65 years are shown in Table [4](#Tab4){ref-type="table"}. The model estimated that RZV would prevent 48,983 HZ cases; 12,136 PHN cases and 5918 other complications compared with no vaccination over the remaining lifetimes of all individuals included in the model. This corresponds to a reduction of 23--24% in these outcomes leading to 2314 QALYs gained. The vaccination costs would total approximately ¥12.88 billion, but the HZ cases prevented would save almost ¥2.89 billion in direct costs and approximately ¥0.65 billion in indirect costs. These outcomes equate to a cost of ¥4,316,457 and ¥4,036,020 per QALY gained from a payer's and societal perspective, respectively.Table 4Base case analysis results for 1 million Japanese adults aged ≥ 65 years vaccinated with RZV vs. no vaccineOutcomeRZVNo vaccineRZV vs. no vaccineHealth outcomes HZ cases152,103201,086(48,983) PHN cases41,42053,556(12,136) Complication cases15,67220,590(4918) Death due to HZ3542(7)Costs (discounted) Vaccination costs¥12,879,004,440¥0¥12,879,004,440 Direct costs due to HZ¥8,588,964,332¥11,479,632,318(¥2,890,667,986) Indirect costs due to HZ¥1,897,343,257¥2,546,279,452(¥648,936,196)QALYs (discounted) QALYs gained12,589,91312,587,5992314Cost-effectiveness ICER  Payer----¥4,316,457/QALY  Societal----¥4,036,020/QALY*HZ* herpes zoster, *ICER* incremental cost-effectiveness ratio, *PHN* postherpetic neuralgia, *QALY* quality-adjusted life years, *RZV* recombinant zoster vaccine, () refers to savings

Scenario Analysis {#Sec14}
-----------------

In scenario analyses, the starting age at vaccination was varied from 50 to 70 years (Table [5](#Tab5){ref-type="table"}). From a payer's perspective, the ICER for people aged ≥ 65 years was the lowest among the four scenarios, though the differences were relatively small. Incremental QALYs increased with increasing age at vaccination, likely because of the higher incidence of HZ in the older age groups. At the same time, incremental costs increased with increasing age at vaccination resulting in ICERs that were similar across the four scenarios tested.Table 5Scenario analysis results for 1 million Japanese adultsAgePayer's perspectiveSocietal perspectiveIncremental cost (¥)Incremental QALYICER (¥/QALY)Incremental cost (¥)Incremental QALYICER (¥/QALY)Base case≥ 659,988,336,45523144,316,4579,339,400,25923144,036,020Scenario 1≥ 509,838,441,49121774,518,4659,024,002,32021774,144,421Scenario 2≥ 609,920,792,66122884,336,2029,230,655,77222884,034,556Scenario 3≥ 7010,123,202,68523144,374,1929,529,813,54023144,117,791*ICER* incremental cost-effectiveness ratio; *QALY* quality-adjusted life years

Sensitivity Analysis {#Sec15}
--------------------

One-way DSA for Japanese adults aged ≥ 65 showed that the ICERs for the payer's and societal perspectives were most sensitive to the following inputs based on their defined ranges: annual waning of two-dose RZV efficacy for individuals aged ≥ 70 years, proportion of patients with HZ developing PHN, HZ incidence, vaccine price and QALY loss per HZ case with PHN (Fig. [1](#Fig1){ref-type="fig"}). Changing the second dose compliance rate and initial efficacy of RZV had little impact on the ICER (data not shown). Threshold analyses showed that increasing either price or waning by approximately 20% would lead to an ICER close to the WTP threshold of ¥5,000,000/QALY. Also, decreasing the efficacy of RZV (two doses), HZ incidence or QALY loss per HZ case by approximately 10% would lead to ICERs close to the WTP threshold (Fig. [2](#Fig2){ref-type="fig"}). PSA demonstrated that 72.2% of simulations from a payer's perspective and 79.7% of simulations from a societal perspective resulted in an ICER below the commonly used WTP threshold of ¥5,000,000 per QALY gained (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}).Fig. 1Deterministic sensitivity analysis results of ICER for Japanese adults aged ≥ 65 years by analytical perspective (top 10). **a** Payer's perspective; **b** societal perspective. *HZ* herpes zoster, *ICER* incremental cost-effectiveness ratio, *PHN* postherpetic neuralgia, *QALY* quality-adjusted life year, *RZV* recombinant zoster vaccine, *YOA* years of age Fig. 2Threshold analysis result for Japanese adults aged ≥ 65 years from payers' perspective. *HZ* herpes zoster, *PHN* postherpetic neuralgia, *QALY* quality-adjusted life year, *RZV* recombinant zoster vaccine Fig. 3Probabilistic sensitivity analysis results of 5000 Monte-Carlo simulations for Japanese adults aged ≥ 65 years by analytical perspective. **a** Payer's perspective; **b** societal perspective. *PSA* probabilistic sensitivity analysis, *QALY* quality-adjusted life year Fig. 4Cost-effectiveness acceptability curve for Japanese adults aged ≥ 65 years by analytical perspective. **a** Payer's perspective; **b** societal perspective. *QALY* quality-adjusted life year, *WTP* willingness to pay

Discussion {#Sec16}
==========

In this study, we presented the cost-effectiveness of RZV compared with no vaccination against HZ in Japanese adults aged ≥ 65 years using the ZONA model established by Curran et al. \[[@CR21]\]. In the base case and under the model assumptions, the ICER of RZV compared with no vaccination was ¥4,320,000 and ¥4,040,000 per QALY gained from a payer's and the societal perspective, respectively. These ICERs are well below the WTP threshold of ¥5,000,000 commonly used in Japan. Scenario analyses where the starting age for introducing RZV vaccination was changed to 50, 60 or ≥ 70 years yielded less favourable ICERs, though differences were relatively small. In the base-case analysis, vaccination age was set to ≥ 65 years, which coincides with the recommended vaccination age for other vaccines (influenza and pneumococcal) included in the national immunization programme for older adults. Therefore, vaccination with RZV at ≥ 65 years is considered a reasonable strategy.

Recently, the cost-effectiveness of varicella vaccination as HZ protection in individuals aged ≥ 65 years has been reported \[[@CR18]\]. This study suggested VVL to be cost-effective in Japanese adults aged ≥ 65 years. However, VVL is not included in the publicly funded immunization programme.

DSA suggested that the cost-effectiveness of RZV vs. no vaccination was most sensitive to assumptions regarding the waning of VE, especially for two-dose RZV in individuals aged ≥ 70 years. Other parameters impacting the ICER included the proportion of patients with HZ developing PHN, HZ incidence, vaccine price and QALY loss for HZ with PHN. These parameters were similar to those identified in cost-effectiveness studies of ZVL vaccination \[[@CR37], [@CR38]\].

Waning rates, to which the ICER proved most sensitive, were estimated based on efficacy data observed in the ZOE-50 and ZOE-70 trials with the caveat of a short follow-up period of just under 4 years \[[@CR32]\]. In a phase IIIb open, long-term extension study in 70 individuals having received two RZV doses as part of the ZOE trials, humoral immune response was evaluated up to 9 years post vaccination. This study showed that the initial increase in VZV-specific immune markers declined over the first 48 months after vaccination. However, cell-mediated and humoral response plateaued after 4 years after vaccination to a level at least threefold above the pre-vaccination level and remained stable throughout year 9 \[[@CR39]\]. No suspected case of HZ was reported during this extension study. These preliminary data suggest that RZV waning may remain stable after 4 years from vaccination up to at least 9 years after vaccination. The ICER was also sensitive to the proportion of people developing PHN following an episode of HZ. The base case probability of developing PHN (19.7%) was taken from the same data source as HZ incidence \[[@CR7]\]. In another Japanese prospective cohort study, a PHN proportion of 9.2% was reported, approximately 50% lower than the base-case value \[[@CR25]\]. Therefore, in one-way DSA, the age-specific PHN proportion was reduced by 50%, which represents the lower bound of values reported in cost-effectiveness analyses of herpes zoster vaccination \[[@CR38], [@CR40]\]. The resulting ICER increased by almost 50%. In a systematic review, the risk of developing PHN was reported to vary from 5% to \> 30% and was highly dependent on study design, age distribution and definition of PHN \[[@CR5]\]. Varying HZ incidence affected RZV cost-effectiveness as well as the public health impact of RZV vaccination \[[@CR19]\]. Epidemiological trends suggest an increase in HZ incidence over time \[[@CR5], [@CR9]\]. In the Miyazaki study, which prospectively followed Japanese individuals of all ages over a time period of 20 years, the incidence of HZ in 2017 was 1.68 times higher than that in 1996 \[[@CR27]\]. A White Paper by the Japanese Government on the ageing population estimated that the number of Japanese adults aged ≥ 65 years increases for at least 20 years from now and reaches 38.1% by 2060 \[[@CR41]\]. In the absence of an effective HZ prevention strategy, this would translate into an increase in health care costs associated with HZ and its complications. Even though variation of some parameters resulted in ICERs above the WTP of ¥5,000,000, all ICERs would remain acceptable when using an alternative WTP of ¥6,350,000 to ¥6,750,000 per QALY gained as proposed by Ohkusa et al. \[[@CR42]\].

One of the strengths of our model is the use of recently published Japanese epidemiological, cost and utility data \[[@CR7], [@CR10], [@CR11]\]. Although there is considerable uncertainty around different parameters, such as VE in the real-world setting and over time as well as coverage and compliance, results were relatively robust under DSA and PSA.

The model has several limitations mostly related to the lack of real-world data and uncertainty around specific parameters to inform the model. Data from extended follow-up studies are needed to refine estimates of waning and RZV effectiveness in clinical practice. It should be noted that varying VE of RZV had little impact on cost-effectiveness within the range of parameters analyzed. In addition, there is no real-life data regarding second dose compliance for RZV in Japan. In the base-case analysis, a second dose compliance rate of 95% was assumed, based on clinical trial data \[[@CR30], [@CR31]\]. Compliance rates ≥ 95% for multiple-dose paediatric vaccines were reported in the Japanese setting. Even though these observations are not generalizable to other age groups, these results suggest that high compliance rates are achievable in Japan. Setting the second dose compliance rate to 70%, as for the US and German setting, had little impact on the ICER, although the number of HZ cases avoided would be 15% lower \[[@CR19]\]. Finally, a review of epidemiological studies suggested that \> 30% of patients with PHN experienced persistent pain for \> 1 year \[[@CR5]\]. In our model, the impact of PHN on utility and costs was only counted during one annual cycle. If the model allowed for PHN to last \> 1 year the resulting ICER would decrease. In the future, coverage and compliance data from national surveillance studies as well as real-life effectiveness data need to be incorporated into the model to provide a more accurate estimate of RZV cost-effectiveness.

Overall, our model showed that the RZV vaccination strategy against HZ is cost-effective compared with no vaccination in Japanese adults ≥ 65 years and that these results were stable under a wide range of parameters tested.

Conclusions {#Sec17}
===========

Recombinant zoster vaccine is a new HZ-specific vaccine that has recently been licensed in Japan for the prevention of HZ in individuals ≥ 50. The current study showed that RZV would be cost-effective in Japanese adults aged ≥ 65 years compared with no vaccination. RZV was cost-effective under a wide range of alternative parameters and assumptions explored.

The summary slide presents a summary of the context, outcomes and impact of this study for healthcare providers.
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